

Biological evaluation of medical devices - Part 10: Tests for irritation and skin sensitization (ISO 10993-10:2010)

This document is a preview generated by EVS

EESTI STANDARDI EESSÕNA

NATIONAL FOREWORD

See Eesti standard EVS-EN ISO 10993-10:2013 sisaldab Euroopa standardi EN ISO 10993-10:2013 ingliskeelset teksti.	This Estonian standard EVS-EN ISO 10993-10:2013 consists of the English text of the European standard EN ISO 10993-10:2013.
Standard on jõustunud sellekohase teate avaldamisega EVS Teatajas.	This standard has been endorsed with a notification published in the official bulletin of the Estonian Centre for Standardisation.
Euroopa standardimisorganisatsioonid on teinud Euroopa standardi rahvuslikele liikmetele kättesaadavaks 21.08.2013.	Date of Availability of the European standard is 21.08.2013.
Standard on kättesaadav Eesti Standardikeskusest.	The standard is available from the Estonian Centre for Standardisation.

Tagasisidet standardi sisu kohta on võimalik edastada, kasutades EVS-i veebilehel asuvat tagasiside vormi või saates e-kirja meiliaadressile standardiosakond@evs.ee.

ICS 11.100.20

Standardite reprodutseerimise ja levitamise õigus kuulub Eesti Standardikeskusele

Andmete paljundamine, taastekitamine, kopeerimine, salvestamine elektroonsesse süsteemi või edastamine ükskõik millises vormis või millisel teel ilma Eesti Standardikeskuse kirjaliku loata on keelatud.

Kui Teil on küsimusi standardite autorikaitse kohta, võtke palun ühendust Eesti Standardikeskusega:
Aru 10, 10317 Tallinn, Eesti; www.evs.ee; telefon 605 5050; e-post info@evs.ee

The right to reproduce and distribute standards belongs to the Estonian Centre for Standardisation

No part of this publication may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, without a written permission from the Estonian Centre for Standardisation.

If you have any questions about copyright, please contact Estonian Centre for Standardisation:
Aru 10, 10317 Tallinn, Estonia; www.evs.ee; phone 605 5050; e-mail info@evs.ee

English Version

**Biological evaluation of medical devices - Part 10: Tests for
irritation and skin sensitization (ISO 10993-10:2010)**

Évaluation biologique des dispositifs médicaux - Partie 10:
Essais d'irritation et de sensibilisation cutanée (ISO 10993-
10:2010)

This European Standard was approved by CEN on 9 July 2013.

CEN members are bound to comply with the CEN/CENELEC Internal Regulations which stipulate the conditions for giving this European Standard the status of a national standard without any alteration. Up-to-date lists and bibliographical references concerning such national standards may be obtained on application to the CEN-CENELEC Management Centre or to any CEN member.

This European Standard exists in three official versions (English, French, German). A version in any other language made by translation under the responsibility of a CEN member into its own language and notified to the CEN-CENELEC Management Centre has the same status as the official versions.

CEN members are the national standards bodies of Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, Former Yugoslav Republic of Macedonia, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and United Kingdom.



EUROPEAN COMMITTEE FOR STANDARDIZATION
COMITÉ EUROPÉEN DE NORMALISATION
EUROPÄISCHES KOMITEE FÜR NORMUNG

CEN-CENELEC Management Centre: Avenue Marnix 17, B-1000 Brussels

Foreword

The text of ISO 10993-10:2010 has been prepared by Technical Committee ISO/TC 194 "Biological evaluation of medical devices" of the International Organization for Standardization (ISO) and has been taken over as EN ISO 10993-10:2013 by Technical Committee CEN/TC 206 "Biological evaluation of medical devices" the secretariat of which is held by NEN.

This European Standard shall be given the status of a national standard, either by publication of an identical text or by endorsement, at the latest by February 2014, and conflicting national standards shall be withdrawn at the latest by February 2014.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. CEN [and/or CENELEC] shall not be held responsible for identifying any or all such patent rights.

This document supersedes EN ISO 10993-10:2010.

This document has been prepared under a mandate given to CEN by the European Commission and the European Free Trade Association, and supports essential requirements of EU Directives.

For relationship with EU Directives, see informative Annex ZA and ZB, which are integral parts of this document.

According to the CEN-CENELEC Internal Regulations, the national standards organizations of the following countries are bound to implement this European Standard: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, Former Yugoslav Republic of Macedonia, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and the United Kingdom.

Endorsement notice

The text of ISO 10993-10:2010 has been approved by CEN as EN ISO 10993-10:2013 without any modification.

Annex ZA (informative)

Relationship between this European Standard and the Essential Requirements of EU Directive 93/42/EEC on Medical Devices

This European Standard has been prepared under a mandate given to CEN by the European Commission and the European Free Trade Association to provide a means of conforming to Essential Requirements of the New Approach Directive 93/42/EEC on Medical Devices.

Once this standard is cited in the Official Journal of the European Union under that Directive and has been implemented as a national standard in at least one Member State, compliance with the clauses of this International Standard given in Table ZA.1 confers, within the limits of the scope of this European Standard, a presumption of conformity with the corresponding Essential Requirements of that Directive and associated EFTA regulations.

Table ZA.1 — Correspondence between this European Standard and Directive 93/42/EEC on medical devices

Clause(s)/sub-clause(s) of this European Standard	Essential Requirements (ERs) of Directive 93/42/EEC	Qualifying remarks/Notes
4, 5, 6, 7, 8, Annexes A, B and C	7.1 first and second indents only	ER 7.1 is only partly covered by EN ISO 10993-10, since the standard does not provide requirements on design and manufacture. However, this standard provides a means to assess irritancy and skin sensitization to substances used in the manufacture of medical devices. Other forms of toxicity and flammability are not covered.
4, 5, 6, 7, 8, Annexes A, B and C	7.2	ER 7.2 is only partly covered by EN ISO 10993-10, since the standard does not provide requirements on design, manufacture and packaging. However, this standard provides a means to assess irritancy and skin sensitization to contaminants and residues in medical devices.
4, 5, 6, 7, 8, Annexes A, B and C	7.5 first sentence of the first paragraph only.	ER 7.5 is only partly covered by EN ISO 10993-10, since the standard does not provide requirements on design and manufacture. However, this standard provides a means to assess irritancy and skin sensitization to substances leaking from medical devices.

General Note: Presumption of conformity depends on also complying with all relevant clauses/subclauses of EN ISO 10993-1.

WARNING — Other requirements and other EU Directives may be applicable to the product(s) falling within the scope of this standard.

Annex ZB (informative)

Relationship between this European Standard and the Essential Requirements of EU Directive 90/385/EEC on Active Implantable Medical Devices

This European Standard has been prepared under a mandate given to CEN by the European Commission and the European Free Trade Association to provide a means of conforming to Essential Requirements of the New Approach Directive 90/385/EEC on active Implantable Medical Devices.

Once this Standard is cited in the Official Journal of the European Union under that Directive and has been implemented as a national standard in at least one Member State, compliance with the clauses of this International Standard given in Table ZB.1 confers, within the limits of the scope of this standard, a presumption of conformity with the corresponding Essential Requirements of that Directive and associated EFTA regulations.

Table ZB.1 — Correspondence between this European Standard and Directive 90/385/EEC on Active Implantable Medical Devices

Clause(s)/sub-clause(s) of this European Standard	Essential Requirements (ERs) of Directive 90/385/EEC	Qualifying remarks/Notes
4, 5, 6, 7, 8, Annexes A, B and C	9, first and second indents only	ER 9 is only partly covered by EN ISO 10993-10, since the standard does not provide requirements on design and manufacture. However, this standard provides a means to assess irritancy and skin sensitization to substances used in the manufacture of medical devices. Other forms of toxicity are not covered.

General Note: Presumption of conformity depends on also complying with all relevant clauses/subclauses of ISO 10993-1.

WARNING — Other requirements and other EU Directives may be applicable to the product(s) falling within the scope of this standard.

Contents

Page

Foreword	iv
Introduction.....	vi
1 Scope	1
2 Normative references	1
3 Terms and definitions	2
4 General principles — Step-wise approach	4
5 Pretest considerations	4
5.1 General	4
5.2 Types of material	5
5.3 Information on chemical composition	5
6 Irritation tests	6
6.1 <i>In vitro</i> irritation tests.....	6
6.2 <i>In vivo</i> irritation tests — Factors to be considered in design and selection of <i>in vivo</i> tests	6
6.3 Animal irritation test	7
6.4 Animal intracutaneous (intra-dermal) reactivity test	11
6.5 Human skin irritation test	14
7 Skin sensitization tests	15
7.1 Choice of test methods	15
7.2 Murine Local Lymph Node Assay (LLNA)	15
7.3 Guinea pig assays for the detection of skin sensitization	18
7.4 Important factors affecting the outcome of the test	19
7.5 Guinea pig maximization test (GPMT)	20
7.6 Closed-patch test (Buehler test)	23
8 Key factors in interpretation of test results	26
Annex A (normative) Preparation of materials for irritation/sensitization testing	27
Annex B (normative) Special irritation tests	29
Annex C (normative) Human skin irritation test	44
Annex D (informative) <i>In vitro</i> tests for skin irritation	48
Annex E (informative) Method for the preparation of extracts from polymeric test materials	54
Annex F (informative) Background information	57
Bibliography	61

Introduction

This part of ISO 10993 assesses possible contact hazards from chemicals released from medical devices, which may produce skin and mucosal irritation, eye irritation or skin sensitization.

Some materials that are included in medical devices have been tested, and their skin or mucosal irritation or sensitization potential has been documented. Other materials and their chemical components have not been tested and may induce adverse effects when in contact with human tissue. The manufacturer is thus obliged to evaluate each device for potential adverse effects prior to marketing.

Traditionally, small animal tests are performed prior to testing on humans to help predict human response. More recently, *in vitro* tests as well as human tests have been added as adjuncts or alternatives. Despite progress and considerable effort in this direction, a review of findings suggests that currently no satisfactory *in vitro* test has been devised to eliminate the requirement for *in vivo* testing. Where appropriate, the preliminary use of *in vitro* methods is encouraged for screening purposes prior to animal testing. In order to reduce the number of animals used, this part of ISO 10993 presents a step-wise approach, with review and analysis of test results at each stage. An animal test is usually required prior to human testing.

It is intended that these studies be conducted using Good Laboratory Practice and comply with regulations related to animal welfare. Statistical analysis of data is recommended and should be used whenever appropriate.

This part of ISO 10993 is intended for use by professionals, appropriately qualified by training and experience, who are able to interpret its requirements and judge the outcomes of the evaluation for each medical device, taking into consideration all the factors relevant to the device, its intended use and the current knowledge of the medical device provided by review of the scientific literature and previous clinical experience.

The tests included in this part of ISO 10993 are important tools for the development of safe products, provided that these are executed and interpreted by trained personnel.

This part of ISO 10993 is based on numerous standards and guidelines, including OECD Guidelines, U.S. Pharmacopoeia and the European Pharmacopoeia. It is intended to be the basic document for the selection and conduct of tests enabling evaluation of irritation and dermal sensitization responses relevant to safety of medical materials and devices.

Biological evaluation of medical devices —

Part 10:

Tests for irritation and skin sensitization

1 Scope

This part of ISO 10993 describes the procedure for the assessment of medical devices and their constituent materials with regard to their potential to produce irritation and skin sensitization.

This part of ISO 10993 includes:

- a) pretest considerations for irritation, including *in silico* and *in vitro* methods for dermal exposure;
- b) details of *in vivo* (irritation and sensitization) test procedures;
- c) key factors for the interpretation of the results.

Instructions are given in Annex A for the preparation of materials specifically in relation to the above tests. In Annex B several special irritation tests are described for application of medical devices in areas other than skin.

2 Normative references

The following referenced documents are indispensable for the application of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 10993-1:2009, *Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process*

ISO 10993-2, *Biological evaluation of medical devices — Part 2: Animal welfare requirements*

ISO 10993-9, *Biological evaluation of medical devices — Part 9: Framework for identification and quantification of potential degradation products*

ISO 10993-12, *Biological evaluation of medical devices — Part 12: Sample preparation and reference materials*

ISO 10993-13, *Biological evaluation of medical devices — Part 13: Identification and quantification of degradation products from polymeric medical devices*

ISO 10993-14, *Biological evaluation of medical devices — Part 14: Identification and quantification of degradation products from ceramics*

ISO 10993-15, *Biological evaluation of medical devices — Part 15: Identification and quantification of degradation products from metals and alloys*

ISO 10993-18, *Biological evaluation of medical devices — Part 18: Chemical characterization of materials*

ISO 14155-1, *Clinical investigation of medical devices for human subjects — Part 1: General requirements*

ISO 14155-2, *Clinical investigation of medical devices for human subjects — Part 2: Clinical investigation plans*